After opening the day higher, the benchmark indices continued their downward momentum, ended the session in the red.

Indian equity markets indices witnessed a positive start and traded with marginal gains for most of the session as investors remained cautious amid hopes of a US-India trade deal and FII selling pressure. However, the markets witnessed a late sell-off and settled in red.

At the closing bell, the BSE Sensex closed lower by 170 points (down 0.2%).

Meanwhile, the NSE Nifty closed 48 points lower (down 0.2%).

Tata Steel, Asian Paints, Uand ltraTech Cement are among the top gainers today

Bajaj Finserv, Kotak Mahindra, and HDFC Bank, on the other hand, were among the top losers today.

The GIFT Nifty was trading at  25,495, lower by 36 points at the time of writing.

The BSE MidCap index ended 0.1% lower, and the BSE SmallCap index ended 0.5% higher.

Sectoral indices were trading mixed today, with stocks in the oil & gas sector and the healthcare sector witnessing buying. Meanwhile, stocks in the metal sector and the service sector witnessed selling pressure.

The rupee is trading at Rs 85.4 against the US$.

Gold prices for the latest contract on MCX are trading 0.2% lower at Rs 97,213 per 10 grams.

Meanwhile, silver prices were trading 0.6% higher at Rs 108,25 per 1 kg.
 

M&M Finance Q1 Disbursement Sees Boost

In the news from finance sector, M&M Finance saw a 2.3% increase in shares after the company announced a small rise in the Q1FY26 disbursement.

Mahindra & Mahindra Financial Services (Mahindra Finance) reported a 1% increase in total disbursements to approximately Rs 128 billion (bn) in Q1FY26.

At about Rs 1,218 bn business assets increased by about 15% from June 2024. For Q1FY26, the estimated Collection Efficiency (CE) is 95%, compared to 94% in Q1FY25.

According to the company's estimates, Stage-2 is at 5.8-5.9% and Stage-3 is at approximately 3.8-3.9% as of June 30, 2025. With more than Rs 96 bn in liquidity, the business also has a healthy cash position.

The primary business of Mahindra & Mahindra Financial Services Limited (MMFSL), an NBFC that is a part of the Mahindra Group, is financing the purchase of new and used cars, trucks, construction equipment, and utility vehicles.
 

Tata Power Renewable Hits Solar Milestone

Moving on to the news from power sector, Tata Power Renewables announced on Thursday with the commissioning of a record 752 megawatt (MW) of solar projects in April-June 2025-26, that its total utility-scale operational capacity was 5.6 GW.

According to a statement from the company, Tata Power Renewables, a division of Tata Power, had put 354 MW of solar capacity into service during the same period as the previous 2024-25 fiscal year. Tata Power Renewables attributed elements like advanced engineering practices, supply chain, execution model, and solid vendor partnerships for the timely completion of projects in difficult environments.

The company reported that its total utility-scale operational capacity, which includes 4.6 GW of solar and 1 GW of wind capacity, now stands at 5.6 GW following the Q1 FY26 commissioning. Along with 1 GW of third-party projects, the company also intends to commission 1.7 GW of its utility-owned capacity in FY26. The company develops renewable energy projects that it owns, manages, and maintains, including solar, wind, hybrid, peak, round-the-clock (RTC), floating solar, and storage systems, including battery storage.

Alembic Pharma Acquires Utility Therapeutics

Moving on to the news from pharma sector, Alembic Pharmaceuticals Inc., a fully owned subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics, to increase the variety of UTI medications it offers in the United States.

The deal is anticipated to be finalised within 30 days, and the acquisition cost is roughly $12 million.

The company wants to bring Utility's pipeline and FDA-approved products to the US market.

Developing and approving branded pharmaceutical products to treat urinary tract infections (UTIs) is Utility Therapeutics' area of expertise

Alembic Pharmaceuticals announced earlier on June 30 that the US Food and Drug Administration (USFDA) had granted its abbreviated new drug application (ANDA) for doxorubicin hydrochloride liposome final approval.

Multiple myeloma, AIDS-related Kaposi Sarcoma, and ovarian cancer are among the conditions for which the injection is recommended.

Alembic Pharmaceuticals develops, produces, and markets pharmaceutical products, such as formulations and active pharmaceutical ingredients. The company has five manufacturing facilities and three research and development facilities.

More By This Author:

Sensex Today Trades Higher; Nifty Above 25,450
Sensex Today Ends 288 Points Lower; Nifty Below 25,500
Sensex Today Trades Marginally Higher; Nifty Above 25,550